, Tracking Stock Market Picks
Enter Symbol:
Optimer Pharmaceuticals, Inc. (OPTR) [hlAlert]

up 21.59 %

Optimer Pharmaceuticals, Inc. (OPTR) rated Accumulate with price target $15 by ThinkEquity

Posted on: Thursday,  Aug 6, 2009  8:25 AM ET by ThinkEquity

ThinkEquity rated Accumulate Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) on 08/06/2009. Previously ThinkEquity rated Buy Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) on 02/20/2009.,
when the stock price was $10.51. Since then, Optimer Pharmaceuticals, Inc. has gained 21.60% as of 10/23/2013's recent price of $12.78.
If you would have followed the previous ThinkEquity's recommendation on OPTR, you would have gained 21.59% of your investment in 1706 days.

Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. The Company?s development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. It has two late-stage anti-infective product candidates: fidaxomicin (formerly OPT-80) and prulifloxacin. Fidaxomicin, the Company?s lead product candidate, is an antibiotic in its second Phase III registration trial for the treatment of Clostridium difficile-infections (CDI), the common nosocomial, or hospital acquired diarrhea. Prulifloxacin is a prodrug in the fluoroquinolone class of antibiotics. The Company is developing additional product candidates using its technology, including its Optimer One-Pot Synthesis (OPopS) drug discovery platform. OPopS is a computer-aided technology that enables the rapid and low-cost synthesis of an array of carbohydrate-based compounds.

Research is at the core of everything we do at ThinkEquity, and we're passionate about it. Employing a disciplined and rigorous process, we scrutinize the spectrum of forces at play in the growth sectors we cover. Starting with a top down analysis, we look closely at the megatrends and industry drivers that create opportunities for innovative companies. We then allocate our resources based on a long-range research roadmap that leads to deep domain expertise and a close working knowledge of the technologies, products, services and people that populate the growth sector landscape. In short, the sum result of the ThinkEquity research process is to identify and affiliate ourselves with the fastest growing private and public companies within our domain verticals.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/6/2009 8:25 AM Buy
14.26 15.00
as of 12/31/2009
1 Week down  -0.09 %
1 Month down  -1.27 %
3 Months down  -19.88 %
1 YTD down  -23.98 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/20/2009 8:25 AM Buy
10.51 14.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy